Leilei Niu

Biography

 Leilei Niu earned her MS from Shandong University in 2014, and now pursuits PhD at The Chinese University of Hong Kong. Her previous study focused on the contribution of inflammation to docetaxel resistance in prostate cancer. She successfully identified Marchantin M, which is a naturally occurring compound; can be used to overcome docetaxel resistance through exerting its anti-inflammatory activity (Leilei Niu. Cancer lett, 2014). Her PhD study mainly focuses on the effect of cellular senescence on sorafenib efficacy in hepatocellular carcinoma, and now some novel findings have been obtained. During the period between Dec 01, 2016 and Feb 15, 2017, she was invited to work as a Post-graduate fellow in Sidi Chen lab (http://medicine.yale.edu/lab/sidichen/people/sidi_chen.profile), Yale University School of Medicine

Research Interest

Surgery